Sanjay J. Mathew, MD

Ketamine formulation study is ‘groundbreaking’

Publish date: April 24, 2018

Dr. Sanjay J. Mathew says the phase 2 study on treating patients with depression who are at a high risk of suicide is a “promising start.”